Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program PRINCETON, N.J. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today
